Anticancer Polymeric Nanomedicines

References

• Farokhzad , O. C. and Langer , R. 2006 . Nanomedicine: Developing smarter therapeutic and diagnostic modalities . Adv. Drug Deliv. Rev. , 58 : 1456 – 1459 .
   PubMed Web of Science ®Google Scholar
• Duncan , R. 2006 . Polymer conjugates as anticancer nanomedicines . Nat. Rev. Cancer , 6 : 688 – 701 .
   PubMed Web of Science ®Google Scholar
• Ferrari , M. 2005 . Cancer nanotechnology: Opportunities and challenges . Nat. Rev. Cancer , 5 : 161 – 171 .
   PubMed Web of Science ®Google Scholar
• Nishiyama , N. and Kataoka , K. 2006 . Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery . Pharmacol. Ther. , 112 : 630 – 648 .
   PubMed Web of Science ®Google Scholar
• Moghimi , S. M. , Hunter , A. C. and Murray , J. C. 2005 . Nanomedicine: Current status and future prospects . FASEB J. , 19 : 311 – 330 .
   PubMed Web of Science ®Google Scholar
• Marty , J. J. , Oppenheim , R. C. and Speiser , P. 1978 . Nanoparticles—new colloidal drug delivery system . Pharm. Acta Helv. , 53 : 17 – 23 .
   PubMedGoogle Scholar
• Bangham , A. D. , Standish , M. M. and Watkins , J. C. 1965 . Diffusion of univalent ions across the lamellae of swollen phospholipids . J. Mol. Biol. , 13 : 238 – 252 .
   PubMed Web of Science ®Google Scholar
• Barenholz , Y. 2001 . Liposome application: problems and prospects . Curr. Opin. Colloid Interface Sci. , 6 : 66 – 77 .
   Web of Science ®Google Scholar
• Gref , R. , Minamitake , Y. , Peracchia , M. , Trubetskoy , V. S. , Torchilin , V. P. and Langer , R. 1994 . Biodegradable long‐circulating polymeric nanospheres . Science , 263 : 1600 – 1603 .
   PubMed Web of Science ®Google Scholar
• Lavasanifar , A. , Samuel , J. and Kwon , G. S. 2002 . Poly(ethylene oxide)‐block‐poly(L‐amino acid) micelles for drug delivery . Adv. Drug Deliv. Rev. , 54 : 169 – 190 .
   PubMed Web of Science ®Google Scholar
• Jemal , A. , Siegel , R. , Ward , E. , Murray , T. , Xu , J. , Smigal , C. and Thun , M. J. 2006 . Cancer statistics, 2006 . CA. Cancer J. Clin. , 56 : 106 – 130 .
   PubMed Web of Science ®Google Scholar
• Park , J. W. , Benz , C. C. and Martin , F. J. 2004 . Future directions of liposome‐ and immunoliposome‐based cancer therapeutics . Semin. Oncol. , 31 : 196 – 205 .
   PubMed Web of Science ®Google Scholar
• Noble , C. O. , Kirpotin , D. B. , Hayes , M. E. , Mamot , C. , Hong , K. , Park , J. W. , Benz , C. C. , Marks , J. D. and Drummond , D. C. 2004 . Development of ligand‐targeted liposomes for cancer therapy . Expert Opin. Ther. Targets , 8 : 335 – 353 .
   PubMed Web of Science ®Google Scholar
• Cattel , L. , Ceruti , M. and Dosio , F. 2003 . From conventional to stealth liposomes a new frontier in cancer chemotherapy . Tumori , 89 : 237 – 249 .
   PubMed Web of Science ®Google Scholar
• Patel , G. B. and Sprott , G. D. 1999 . Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems . Crit. Rev. Biotechnol. , 19 : 317 – 357 .
   PubMed Web of Science ®Google Scholar
• Duncan , R. , Ringsdorf , H. and Satchi‐Fainaro , R. 2006 . Polymer therapeutics–polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities . J. Drug Target. , 14 : 337 – 341 .
   PubMed Web of Science ®Google Scholar
• Duncan , R. , Ringsdorf , H. and Satchi‐Fainaro , R. 2006 . Polymer therapeutics: Polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities . Adv. Polym. Sci. , 192 : 1 – 8 .
   Web of Science ®Google Scholar
• Haag , R. and Kratz , F. 2006 . Polymer therapeutics: Concepts and applications . Angew. Chem. Int. Ed. , 45 : 1198 – 1215 .
   PubMed Web of Science ®Google Scholar
• Haag , R. 2004 . Supramolecular drug‐delivery systems based on polymeric core‐shell architectures . Angew. Chem. Int. Ed. , 43 : 278 – 282 .
   PubMed Web of Science ®Google Scholar
• Torchilin , V. P. 2005 . Block copolymer micelles as a solution for drug delivery problems . Expert Opin. Therapeutic Pat. , 15 : 63 – 75 .
   Web of Science ®Google Scholar
• Torchilin , V. P. 2004 . Targeted polymeric micelles for delivery of poorly soluble drugs . Cell. Mol. Life Sci. , 61 : 2549 – 2559 .
   PubMed Web of Science ®Google Scholar
• Kataoka , K. , Harada , A. and Nagasaki , Y. 2001 . Block copolymer micelles for drug delivery: Design, characterization and biological significance . Adv. Drug Deliv. Rev. , 47 : 113 – 131 .
   PubMed Web of Science ®Google Scholar
• Jones , M. C. and Leroux , J. C. 1999 . Polymeric micelles—a new generation of colloidal drug carriers . Eur. J. Pharm. Biopharm. , 48 : 101 – 111 .
   PubMed Web of Science ®Google Scholar
• Kwon , G. S. and Kataoka , K. 1995 . Block‐copolymer micelles as long‐circulating drug vehicles . Adv. Drug Deliv. Rev. , 16 : 295 – 309 .
   Web of Science ®Google Scholar
• Savic , R. , Eisenberg , A. and Maysinger , D. 2006 . Block copolymer micelles as delivery vehicles of hydrophobic drugs: Micelle‐cell interactions . J. Drug Target. , 14 : 343 – 355 .
   PubMed Web of Science ®Google Scholar
• Nishiyama , N. and Kataoka , K. 2006 . Nanostructured devices based on block copolymer assemblies for drug delivery: Designing structures for enhanced drug function . Adv. Polym. Sci. , 193 : 67 – 101 .
   Web of Science ®Google Scholar
• Allen , T. M. and Cullis , P. R. 2004 . Drug delivery systems: Entering the mainstream . Science , 303 : 1818 – 1822 .
   PubMed Web of Science ®Google Scholar
• Svenson , S. and Tomalia , D. A. 2005 . Commentary‐Dendrimers in biomedical applications‐reflections on the field . Adv. Drug Deliv. Rev. , 57 : 2106 – 2129 .
   PubMed Web of Science ®Google Scholar
• Lee , C. C. , MacKay , J. A. , Frechet , J. M. J. and Szoka , F. C. 2005 . Designing dendrimers for biological applications . Nat. Biotechnol. , 23 : 1517 – 1526 .
   PubMed Web of Science ®Google Scholar
• Quintana , A. , Raczka , E. , Piehler , L. , Lee , I. , Myc , A. , Majoros , I. , Patri , A. K. , Thomas , T. , Mule , J. and Baker , J. R. 2002 . Design and function of a dendrimer‐based therapeutic nanodevice targeted to tumor cells through the folate receptor . Pharm. Res. , 19 : 1310 – 1316 .
   PubMed Web of Science ®Google Scholar
• Malik , N. , Evagorou , E. G. and Duncan , R. 1999 . Dendrimer‐platinate: A novel approach to cancer chemotherapy . Anticancer Drugs , 10 : 767 – 776 .
   PubMed Web of Science ®Google Scholar
• Lee , C. C. , Gillies , E. R. , Fox , M. E. , Guillaudeu , S. J. , Frechet , J. M. J. , Dy , E. E. and Szoka , F. C. 2006 . A single dose of doxorubicin‐functionalized bow‐tie dendrimer cures mice bearing C‐26 colon carcinomas . Proc. Natl. Acad. Sci. U.S.A. , 103 : 16649 – 16654 .
   PubMed Web of Science ®Google Scholar
• Discher , D. E. and Ahmed , F. 2006 . Polymersomes . Annu. Rev. Biomed. Eng. , 8 : 323 – 341 .
   PubMed Web of Science ®Google Scholar
• Discher , D. E. and Eisenberg , A. 2002 . Polymer vesicles . Science , 297 : 967 – 973 .
   PubMed Web of Science ®Google Scholar
• Holowka , E. P. , Sun , V. Z. , Kamei , D. T. and Deming , T. J. 2006 . Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery . Nat. Mater. ,
   Google Scholar
• Bellomo , E. G. , Wyrsta , M. D. , Pakstis , L. , Pochan , D. J. and Deming , T. J. 2004 . Stimuli‐responsive polypeptide vesicles by conformation‐specific assembly . Nat. Mater. , 3 : 244 – 248 .
   PubMed Web of Science ®Google Scholar
• Photos , P. J. , Bacakova , L. , Discher , B. , Bates , F. S. and Discher , D. E. 2003 . Polymer vesicles in vivo: Correlations with PEG molecular weight . J. Controlled Release , 90 : 323 – 334 .
   PubMed Web of Science ®Google Scholar
• Yu , K. , Zhang , L. F. and Eisenberg , A. 1996 . Novel morphologies of “crew‐cut” aggregates of amphiphilic diblock copolymers in dilute solution . Langmuir , 12 : 5980 – 5984 .
   Web of Science ®Google Scholar
• Vauthey , S. , Santoso , S. , Gong , H. Y. , Watson , N. and Zhang , S. G. 2002 . Molecular self‐assembly of surfactant‐like peptides to form nanotubes and nanovesicles . Proc. Natl. Acad. Sci. U. S. A. , 99 : 5355 – 5360 .
   PubMed Web of Science ®Google Scholar
• Gros , L. , Ringsdorf , H. and Schupp , H. 1981 . Polymeric anti‐tumor agents on a molecular and on a cellular‐level . Angew. Chem. Int. Ed. Engl. , 20 : 305 – 325 .
   Web of Science ®Google Scholar
• Ringsdorf , H. 1975 . Structure and properties of pharmacologically active polymers . Journal of Polym. Sci. Polym. Symp. , : 135 – 153 .
   Google Scholar
• Duncan , R. and Kopecek , J. 1984 . Soluble synthetic polymers as potential drug carriers . Adv. Polym. Sci. , 57 : 51 – 101 .
   Web of Science ®Google Scholar
• Duncan , R. 2003 . The dawning era of polymer therapeutics . Nat. Rev. Drug Discov. , 2 : 347 – 360 .
   PubMed Web of Science ®Google Scholar
• Maeda , H. 2001 . SMANCS and polymer‐conjugated macromolecular drugs: Advantages in cancer chemotherapy . Adv. Drug Deliv. Rev. , 46 : 169 – 185 .
   PubMed Web of Science ®Google Scholar
• Qiu , L. Y. and Bae , Y. H. 2006 . Polymer architecture and drug delivery . Pharm. Res. , 23 : 1 – 30 .
   PubMed Web of Science ®Google Scholar
• Folkman , J. and Long , D. M. 1964 . The use of silicone rubber as a carrier for prolonged drug therapy . J. Surg. Res. , 4 : 139 – 142 .
   PubMed Web of Science ®Google Scholar
• Langer , R. and Folkman , J. 1976 . Polymers for sustained‐release of proteins and other macromolecules . Nature , 263 : 797 – 800 .
   PubMed Web of Science ®Google Scholar
• Westphal , M. , Hilt , D. C. , Bortey , E. , Delavault , P. , Olivares , R. , Warnke , P. C. , Whittle , I. R. , Jaaskelainen , J. and Ram , Z. 2003 . A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma . Neuro‐Oncology , 5 : 79 – 88 .
   PubMed Web of Science ®Google Scholar
• Brem , H. and Gabikian , P. 2001 . Biodegradable polymer implants to treat brain tumors . J. Controlled Release , 74 : 63 – 67 .
   PubMed Web of Science ®Google Scholar
• Brem , H. , Walter , K. A. and Langer , R. 1993 . Polymers as controlled drug delivery devices for the treatment of malignant brain‐tumors . Eur. J. Pharm. Biopharm. , 39 : 2 – 7 .
   Web of Science ®Google Scholar
• Galindo‐Rodriguez , S. , Allemann , E. , Fessi , H. and Doelker , E. 2004 . Physicochemical parameters associated with nanoparticle formation in the salting‐out, emulsification‐diffusion, and nanoprecipitation methods . Pharm. Res. , 21 : 1428 – 1439 .
   PubMed Web of Science ®Google Scholar
• Kakizawa , Y. and Kataoka , K. 2002 . Block copolymer micelles for delivery of gene and related compounds . Adv. Drug Deliv. Rev. , 54 : 203 – 222 .
   PubMed Web of Science ®Google Scholar
• Discher , B. M. , Won , Y. Y. , Ege , D. S. , Lee , J. C. M. , Bates , F. S. , Discher , D. E. and Hammer , D. A. 1999 . Polymersomes: Tough vesicles made from diblock copolymers . Science , 284 : 1143 – 1146 .
   PubMed Web of Science ®Google Scholar
• Holowka , E. P. , Pochan , D. J. and Deming , T. J. 2005 . Charged polypeptide vesicles with controllable diameter . J. Am. Chem. Soc. , 127 : 12423 – 12428 .
   PubMed Web of Science ®Google Scholar
• Lyczak , J. B. and Morrison , S. L. 1994 . Biological and pharmacokinetic properties of a novel immunoglobulin‐Cd4 fusion protein . Arch. Virol. , 139 : 189 – 196 .
   Google Scholar
• Davis , F. , Abuchowski , A. , Van Es , T. , Palczuk , N. , Chen , R. , Savoca , K. and Wieder , K. 1978 . Enzyme Eng. , 4 : 169
   Google Scholar
• Wieder , K. J. , Palczuk , N. C. , van Es , T. and Davis , F. F. 1979 . Some properties of polyethylene glycol: Phenylalanine ammonia‐lyase adducts . J. Biol. Chem. , 254 : 12579 – 12587 .
   PubMed Web of Science ®Google Scholar
• Wang , Y. S. , Youngster , S. , Grace , M. , Bausch , J. , Bordens , R. and Wyss , D. F. 2002 . Structural and biological characterization of pegylated recombinant interferon alpha‐2b and its therapeutic implications . Adv. Drug Deliv. Rev. , 54 : 547 – 570 .
   PubMed Web of Science ®Google Scholar
• Wagner , V. , Dullaart , A. , Bock , A. K. and Zweck , A. 2006 . The emerging nanomedicine landscape . Nat. Biotechnol. , 24 : 1211 – 1217 .
   PubMed Web of Science ®Google Scholar
• Shaunak , S. , Godwin , A. , Choi , J. W. , Balan , S. , Pedone , E. , Vijayarangam , D. , Heidelberger , S. , Teo , I. , Zloh , M. and Brocchini , S. 2006 . Site‐specific PEGylation of native disulfide bonds in therapeutic proteins . Nat. Chem. Biol. , 2 : 312 – 313 .
   PubMed Web of Science ®Google Scholar
• Kolb , H. C. , Finn , M. G. and Sharpless , K. B. 2001 . Click chemistry: Diverse chemical function from a few good reactions . Angew. Chem. Int. Ed. , 40 : 2004 – 2021 .
   PubMed Web of Science ®Google Scholar
• Demko , Z. P. and Sharpless , K. B. 2002 . A click chemistry approach to tetrazoles by Huisgen 1,3‐dipolar cycloaddition: Synthesis of 5‐sulfonyl tetrazoles from azides and sulfonyl cyanides . Angew. Chem. Int. Ed. , 41 : 2110 – 2113 .
   PubMed Web of Science ®Google Scholar
• Manetsch , R. , Krasinski , A. , Radic , Z. , Raushel , J. , Taylor , P. , Sharpless , K. B. and Kolb , H. C. 2004 . In situ click chemistry: Enzyme inhibitors made to their own specifications . J. Am. Chem. Soc. , 126 : 12809 – 12818 .
   PubMed Web of Science ®Google Scholar
• Sawa , M. , Hsu , T. L. , Itoh , T. , Sugiyama , M. , Hanson , S. R. , Vogt , P. K. and Wong , C. H. 2006 . Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo . Proc. Natl. Acad. Sci. U. S. A. , 103 : 12371 – 12376 .
   PubMed Web of Science ®Google Scholar
• Zhang , K. C. , Diehl , M. R. and Tirrell , D. A. 2005 . Artificial polypeptide scaffold for protein immobilization . J. Am. Chem. Soc. , 127 : 10136 – 10137 .
   PubMed Web of Science ®Google Scholar
• Gopin , A. , Ebner , S. , Attali , B. and Shabat , D. 2006 . Enzymatic activation of second‐generation dendritic prodrugs: Conjugation of self‐immolative dendrimers with poly(ethylene glycol) via click chemistry . Bioconjug. Chem. , 17 : 1432 – 1440 .
   PubMed Web of Science ®Google Scholar
• Beatty , K. E. , Xie , F. , Wang , Q. and Tirrell , D. A. 2005 . Selective dye‐labeling of newly synthesized proteins in bacterial cells . J. Am. Chem. Soc. , 127 : 14150 – 14151 .
   PubMed Web of Science ®Google Scholar
• Kwon , I. , Wang , P. and Tirrell , D. A. 2006 . Design of a bacterial host for site‐specific incorporation of p‐bromophenylalanine into recombinant proteins . J. Am. Chem. Soc. , 128 : 11778 – 11783 .
   PubMed Web of Science ®Google Scholar
• Minko , T. , Paranjpe , P. V. , Qiu , B. , Lalloo , A. , Won , R. , Stein , S. and Sinko , P. J. 2002 . Enhancing the anticancer efficacy of camptothecin using biotinylated poly (ethyleneglycol) conjugates in sensitive and multidrug‐resistant human ovarian carcinoma cells . Cancer Chemother. Pharmacol. , 50 : 143 – 150 .
   PubMed Web of Science ®Google Scholar
• Thomson , A. H. , Vasey , P. A. , Murray , L. S. , Cassidy , J. , Fraier , D. , Frigerio , E. and Twelves , C. 1999 . Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours . Br. J. Cancer , 81 : 99 – 107 .
   PubMed Web of Science ®Google Scholar
• Chandran , S. , Nan , A. , Ghandehari , H. and Denmeade , S. R. 2005 . An HPMA‐prodrug conjugate as a novel strategy for treatment of prostate cancer . Clin. Cancer Res. , 11 : 9004s – 9004s .
   Google Scholar
• Jelinkova , M. , Rihova , B. , Etrych , T. , Strohalm , J. , Ulbrich , K. , Kubackova , K. and Rozprimova , L. 2001 . Antitumor activity of antibody‐targeted HPMA copolymers of doxorubicin in experiment and clinical practice . Clin. Cancer Res. , 7 : 3677s – 3678s .
   Google Scholar
• Calolfa , V. R. , Zamai , M. , Ghiglieri , A. , Farao , M. , vandeVen , M. , Gratton , E. , Castelli , M. G. , Suarato , A. and Geroni , A. C. 2000 . In vivo biodistribution and antitumor activity of novel HPMA‐copolymers of camptothecin . Clin. Cancer Res. , 6 : 4490s – 4491s .
   Google Scholar
• Greenwald , R. B. , Conover , C. D. and Choe , Y. H. 2000 . Poly(ethylene glycol) conjugated drugs and prodrugs: A comprehensive review . Crit. Rev. Ther. Drug Carrier Syst. , 17 : 101 – 161 .
   PubMed Web of Science ®Google Scholar
• Pendri , A. , Conover , C. D. and Greenwald , R. B. 1998 . Antitumor activity of paclitaxel‐2′‐glycinate conjugated to poly(ethylene glycol): a water‐soluble prodrug . Anticancer Drug Des. , 13 : 387 – 395 .
   PubMedGoogle Scholar
• Conover , C. D. , Greenwald , R. B. , Pendri , A. , Gilbert , C. W. and Shum , K. L. 1998 . Camptothecin delivery systems: Enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker . Cancer Chemother. Pharmacol. , 42 : 407 – 414 .
   PubMed Web of Science ®Google Scholar
• Conover , C. D. , Pendri , A. , Lee , C. , Gilbert , C. W. , Shum , K. L. and Greenwald , R. B. 1997 . Camptothecin delivery systems: The antitumor activity of a camptothecin 20‐0‐polyethylene glycol ester transport form . Anticancer Res. , 17 : 3361 – 3368 .
   PubMed Web of Science ®Google Scholar
• Greenwald , R. B. , Pendri , A. , Conover , C. D. , Gilbert , C. W. , Yang , R. and Xia , J. 1996 . Drug delivery systems. 2. Camptothecin 20‐O‐poly(ethylene glycol) ester transport forms . J. Med. Chem. , 39 : 1938 – 1940 .
   PubMed Web of Science ®Google Scholar
• Bhatt , R. , Vries , P. D. , Tulinsky , J. , Bellamy , G. , Baker , B. , Singer , J. W. and Klein , P. 2003 . Synthesis and in vivo antitumor activity of poly(L‐glutamic acid) conjugates of 20(S)‐camptothecin . J. Med. Chem. , 46 : 190 – 193 .
   PubMed Web of Science ®Google Scholar
• Singer , J. W. , Bhatt , R. , Tulinsky , J. , Buhler , K. R. , Heasley , E. , Klein , P. and Vries , P. D. 2001 . Water‐soluble poly‐(L‐glutamic acid)‐gly‐camptothecinconjugates enhance camptothecin stability and efficacy in vivo . J. Controlled Release , 74 : 243 – 247 .
   PubMed Web of Science ®Google Scholar
• Li , C. 1998 . Complete regression of well‐established tumors using a novel water‐soluble poly (L‐glutamic acid)‐paclitaxel conjugate . Cancer Res. , 58 : 2404 – 2409 .
   PubMed Web of Science ®Google Scholar
• Zou , Y. , Wu , Q. , Tansey , W. , Chow , D. , Hung , M. , Charnsangavej , C. , Wallace , S. and Li , C. 2001 . Effectiveness of water soluble poly(L‐glutamic acid)‐camptothecin conjugate against resistant human lung cancer xenografted in nude mice . Int. J. Oncol. , 18 : 331 – 336 .
   PubMed Web of Science ®Google Scholar
• Mitsui , I. , Kumazawa , E. , Hirota , Y. , Aonuma , M. , Sugimori , M. , Ohsuki , S. , Uoto , K. , Ejima , A. , Terasawa , H. and Sato , K. 1995 . A new water‐soluble camptothecin derivative, Dx‐8951f, exhibits potent antitumor‐activity against human tumors in‐vitro and in‐vivo . Jpn. J. Cancer Res. , 86 : 776 – 782 .
   PubMedGoogle Scholar
• Ochi , Y. , Shiose , Y. , Kuga , H. and Kumazawa , E. 2005 . A possible mechanism for the long‐lasting antitumor effect of the macromolecular conjugate DE‐310: mediation by cellular uptake and drug release of its active camptothecin analog DX‐8951 . Cancer Chemother. Pharmacol. , 55 : 323 – 332 .
   Google Scholar
• Harada , M. , Sakakibara , H. , Yano , T. , Suzuki , T. and Okuno , S. 2000 . Determinants for the drug release from T‐0128, camptothecin analogue‐carboxymethyl dextran conjugate . J. Controlled Release , 69 : 399 – 412 .
   PubMed Web of Science ®Google Scholar
• Harada , M. , Murata , J. , Sakamura , Y. , Sakakibara , H. , Okuno , S. and Suzuki , T. 2001 . Carrier and dose effects on the pharmacokinetics of T‐0128, a camptothecin analogue‐carboxymethyl dextran conjugate, in non‐tumor‐ and tumor‐bearing rats . J. Controlled Release , 71 : 71 – 86 .
   PubMed Web of Science ®Google Scholar
• Cheng , J. , Khin , K. T. and Davis , M. E. 2004 . Antitumor activity of beta‐cyclodextrin polymer‐camptothecin conjugates . Mol. Pharm. , 1 : 183 – 193 .
   PubMed Web of Science ®Google Scholar
• Cheng , J. J. , Khin , K. T. , Jensen , G. S. , Liu , A. J. and Davis , M. E. 2003 . Synthesis of linear, beta‐cyclodextrin‐based polymers and their camptothecin conjugates . Bioconjug. Chem. , 14 : 1007 – 1017 .
   PubMed Web of Science ®Google Scholar
• Schluep , T. , Hwang , J. , Cheng , J. J. , Heidel , J. D. , Bartlett , D. W. , Hollister , B. and Davis , M. E. 2006 . Preclinical efficacy of the camptothecin‐polymer conjugate IT‐101 in multiple cancer models . Clin. Cancer Res. , 12 : 1606 – 1614 .
   PubMed Web of Science ®Google Scholar
• Schluep , T. , Cheng , J. J. , Khin , K. T. and Davis , M. E. 2006 . Pharmacokinetics and biodistribution of the camptothecin‐polymer conjugate IT‐101 in rats and tumor‐bearing mice . Cancer Chemother. Pharmacol. , 57 : 654 – 662 .
   PubMed Web of Science ®Google Scholar
• Fuloria , J. , Abubakr , Y. , Perez , R. , Pike , M. and Zalupski , M. 2005 . A phase I trial of [(1‐ 4)‐linked b‐D‐mannopyranose]17‐[(1‐ 6)‐linked‐a‐D‐galactopyranose]10 (DAVANAT) co‐administered with 5‐fluorouracil, in patients with refractory solid tumors . J. Clin. Oncol. , 23 : 3114
   Google Scholar
• Bolling , C. , Graefe , T. , Lubbing , C. , Jankevicius , F. , Uktveris , S. , Cesas , A. , Meyer‐Moldenhauer , W. H. , Starkmann , H. , Weigel , M. , Burk , K. and Hanauske , A. R. 2006 . Phase II study of MTX‐HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma . Invest New Drug , 24 : 521 – 527 .
   PubMed Web of Science ®Google Scholar
• Fossella , F. V. , Lippman , S. M. and Tarasaoff , P. 1995 . Phase I/II study of gemcitabine, an active agent for advanced non‐small cell lung cancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. , 14 : 371
   Google Scholar
• Tolcher , A. , Forouzesh , B. and McCreery , H. 2002 . A Phase I and pharmacokinetic study of BB10901, a maytansinoid immunoconjugate, CD56 expressing tumors . Eur. J. Cancer , 38 : S152 – S153 .
   Google Scholar
• Fossella , F. , McCann , J. , Tolcher , A. , Xie , H. , Hwang , L. L. , Carr , C. , Berg , K. and Fram , R. 2005 . Phase II trial of BB‐10901 (huN901‐DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56‐positive small cell carcinoma . J. Clin. Oncol. (2005 ASCO Annual Meeting Proceedings) , 123 : 16S
   Google Scholar
• Veronese , F. M. , Schiavon , O. , Pasut , G. , Mendichi , R. , Andersson , L. , Tsirk , A. , Ford , J. , Wu , G. F. , Kneller , S. , Davies , J. and Duncan , R. 2005 . PEG‐doxorubicin conjugates: Influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity . Bioconjug. Chem. , 16 : 775 – 784 .
   PubMed Web of Science ®Google Scholar
• Greenwald , R. B. , Pendri , A. , Conover , C. D. , Lee , C. , Choe , Y. H. , Gilbert , C. , Martinez , A. , Xia , J. , Wu , D. C. and Hsue , M. 1998 . Camptothecin‐20‐PEG ester transport forms: the effect of spacer groups on antitumor activity . Bioorg. Med. Chem. , 6 : 551 – 562 .
   PubMed Web of Science ®Google Scholar
• Conover , C. D. , Greenwald , R. B. , Pendri , A. and Shum , K. L. 1999 . Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs . Anticancer Drug Des. , 14 : 499 – 506 .
   PubMedGoogle Scholar
• Greenwald , R. B. , Pendri , A. , Conover , C. , Gilbert , C. , Yang , R. and Xia , J. 1996 . Drug delivery systems. 2. Camptothecin 20‐O‐poly(ethylene glycol)ester transport forms . J. Med. Chem. , 39 : 1938 – 1940 .
   PubMed Web of Science ®Google Scholar
• Rowinsky , E. K. , Rizzo , J. , Ochoa , L. , Takimoto , C. H. , Forouzesh , B. , Schwartz , G. , Hammond , L. A. , Patnaik , A. , Kwiatek , J. , Goetz , A. , Denis , L. , McGuire , J. and Tolcher , A. W. 2003 . A phase I and pharmacokinetic study of pegylated camptothecin as a 1‐hour infusion every 3 weeks in patients with advanced solid malignancies . J. Clin. Oncol. , 21 : 148 – 157 .
   PubMed Web of Science ®Google Scholar
• Greenwald , R. B. , Choe , Y. H. , McGuire , J. and Conover , C. D. 2003 . Effective drug delivery by PEGylated drug conjugates . Adv. Drug Deliv. Rev. , 55 : 217 – 250 .
   PubMed Web of Science ®Google Scholar
• Minko , T. , Paranjpe , P. V. , Qiu , B. , Lalloo , A. , Won , R. , Stein , S. and Sinko , P. J. 2002 . Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug‐resistant human ovarian carcinoma cells . Cancer Chemother. Pharmacol. , 50 : 143 – 150 .
   PubMed Web of Science ®Google Scholar
• Yu , D. S. , Peng , P. , Dharap , S. S. , Wang , Y. , Mehlig , M. , Chandna , P. , Zhao , H. , Filpula , D. , Yang , K. , Borowski , V. , Borchard , G. , Zhang , Z. H. and Minko , T. 2005 . Antitumor activity of poly(ethylene glycol)‐camptothecin conjugate: The inhibition of tumor growth in vivo . J. Controlled Release , 110 : 90 – 102 .
   PubMed Web of Science ®Google Scholar
• Maeda , H. , Wu , J. , Sawa , T. , Matsumura , Y. and Hori , K. 2000 . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review . J. Controlled Release , 65 : 271 – 284 .
   PubMed Web of Science ®Google Scholar
• Seymour , L. , Duncan , R. , Strohalm , J. and Kopecek , J. 1987 . Effect of molecular weight (MW) of N‐(2‐hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats . J. Biomed. Mater. Res. , 21 : 1341 – 1358 .
   PubMed Web of Science ®Google Scholar
• Duncan , R. 1992 . Drug‐polymer conjugates: potential for improved chemotherapy . Anticancer Drugs , 3 : 175 – 210 .
   PubMed Web of Science ®Google Scholar
• Jorgensen , K. E. and Moller , J. V. 1979 . Use of flexible polymers as probes of glomerular pore size . Am. J. Physio. Renal Physiol. , 236 : 103 – 111 .
   PubMed Web of Science ®Google Scholar
• Vasey , P. A. , Kaye , S. B. , Morrison , R. , Twelves , C. , Wilson , P. , Duncan , R. , Thomson , A. H. , Murray , L. S. , Hilditch , T. E. , Murray , T. , Burtles , S. , Fraier , D. , Frigerio , E. and Cassidy , J. 1999 . Phase I clinical and pharmacokinetic study of PK1 [N‐(2‐hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents‐drug‐polymer conjugates. Cancer Research Campaign Phase I/II Committee . Clin. Cancer Res. , 5 : 83 – 94 .
   PubMed Web of Science ®Google Scholar
• Terwogt , J. M. M. , Huinink , W. W. T. , Schellens , J. H. M. , Schot , M. , Mandjes , I. A. M. , Zurlo , M. G. , Rocchetti , M. , Rosing , H. , Koopman , F. J. and Beijnen , J. H. 2001 . Phase I clinical and pharmacokinetic study of PNU166945, a novel water‐soluble polymer‐conjugated prodrug of paclitaxel . Anticancer Drugs , 12 : 315 – 323 .
   PubMed Web of Science ®Google Scholar
• Bissett , D. , Cassidy , J. , de Bono , J. S. , Muirhead , F. , Main , M. , Robson , L. , Fraier , D. , Magne , M. L. , Pellizzoni , C. , Porro , M. G. , Spinelli , R. , Speed , W. and Twelves , C. 2004 . Phase I and pharmacokinetic (PK) study of MAG‐CPT (PNU 166148): a polymeric derivative of camptothecin (CPT) . Br. J. Cancer , 91 : 50 – 55 .
   PubMed Web of Science ®Google Scholar
• Tomlinson , R. , Heller , J. , Brocchini , S. and Duncan , R. 2003 . Polyacetal‐doxorubicin conjugates designed for pH‐dependent degradation . Bioconjug. Chem. , 14 : 1096 – 1106 .
   PubMed Web of Science ®Google Scholar
• Wachters , F. M. , Groen , H. J. M. , Maring , J. G. , Gietema , J. A. , Porro , M. , Dumez , H. , de Vries , E. G. E. and van Oosterom , A. T. 2004 . A phase I study with MAG‐camptothecin intravenously administered weekly for 3 weeks in a 4‐week cycle in adult patients with solid tumours . Br. J. Cancer , 90 : 2261 – 2267 .
   PubMed Web of Science ®Google Scholar
• Sarapa , N. , Britto , M. R. , Speed , W. , Jannuzzo , M. , Breda , M. , James , C. A. , Porro , M. , Rocchetti , M. , Wanders , A. , Mahteme , H. and Nygren , P. 2003 . Assessment of normal and tumor tissue uptake of MAG‐CPT, a polymer‐bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma . Cancer Chemother. Pharmacol. , 52 : 424 – 430 .
   PubMed Web of Science ®Google Scholar
• Seymour , L. W. , Ferry , D. R. , Anderson , D. , Hesslewood , S. , Julyan , P. J. , Poyner , R. , Doran , J. , Young , A. M. , Burtles , S. and Kerr , D. J. 2002 . Hepatic drug targeting: Phase I evaluation of polymer‐bound doxorubicin . J. Clin. Oncol. , 20 : 1668 – 1676 .
   PubMed Web of Science ®Google Scholar
• Bouma , M. , Nuijen , B. , Stewart , D. R. , Rice , J. R. , Jansen , B. A. J. , Reedijk , J. , Bult , A. and Beijnen , J. H. 2002 . Stability and compatibility of the investigational polymer‐conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential . Anticancer. Drugs , 13 : 915 – 924 .
   PubMed Web of Science ®Google Scholar
• Singer , J. W. , Shaffer , S. , Baker , B. , Bernareggi , A. , Stromatt , S. , Nienstedt , D. and Besman , M. 2005 . Paclitaxel poliglumex (XYOTAX; CT‐2103): an intracellularly targeted taxane . Anticancer Drugs , 16 : 243 – 254 .
   PubMed Web of Science ®Google Scholar
• Singer , J. W. 2005 . Paclitaxel poliglumex (XYOTAX, CT‐2103): a macromolecular taxane . J. Control Release , 109 : 120 – 126 .
   PubMed Web of Science ®Google Scholar
• Singer , J. W. , Baker , B. , De Vries , P. , Kumar , A. , Shaffer , S. , Vawter , E. , Bolton , M. and Garzone , P. 2003 . Poly‐(L)‐glutamic acid‐paclitaxel (CT‐2103) [XYOTAX (TM)], a biodegradable polymeric drug conjugate—Characterization, preclinical pharmacology, and preliminary clinical data . Adv. Exp. Med. Biol. , 519 : 81 – 99 .
   PubMed Web of Science ®Google Scholar
• Sabbatini , P. , Aghajanian , C. , Dizon , D. , Anderson , S. , Dupont , J. , Brown , J. V. , Peters , W. A. , Jacobs , A. , Mehdi , A. , Rivkin , S. , Eisenfeld , A. J. and Spriggs , D. 2004 . Phase II study of CT‐2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma . J. Clin. Oncol. , 22 : 4523 – 4531 .
   PubMed Web of Science ®Google Scholar
• Davis , M. E. and Brewster , M. E. 2004 . Cyclodextrin‐based pharmaceutics: Past, present and future . Nat. Rev. Drug Discov. , 3 : 1023 – 1035 .
   PubMed Web of Science ®Google Scholar
• Mocanu , G. , Vizitiu , D. and Carpov , A. 2001 . Cyclodextrin polymers . J. Bioact. Compat. Polym. , 16 : 315 – 342 .
   Web of Science ®Google Scholar
• Szeman , J. , Fenyvesi , E. , Szejtli , J. , Ueda , H. , Machida , Y. and Nagai , T. 1987 . Water‐soluble cyclodextrin polymers‐their interaction with drugs . J. Inclusion Phenomena , 5 : 427 – 431 .
   Google Scholar
• Gonzalez , H. , Hwang , S. J. and Davis , M. E. 1999 . New class of polymers for the delivery of macromolecular therapeutics . Bioconjug. Chem. , 10 : 1068 – 1074 .
   PubMed Web of Science ®Google Scholar
• Cheng , J. J. , Zeidan , R. , Mishra , S. , Liu , A. , Pun , S. H. , Kulkarni , R. P. , Jensen , G. S. , Bellocq , N. C. and Davis , M. E. 2006 . Structure‐function correlation of chloroquine and analogues as transgene expression enhancers in nonviral gene delivery . J. Med. Chem. , 49 : 6522 – 6531 .
   PubMed Web of Science ®Google Scholar
• Pun , S. H. , Tack , F. , Bellocq , N. C. , Cheng , J. J. , Grubbs , B. H. , Jensen , G. S. , Davis , M. E. , Brewster , M. , Janicot , M. , Janssens , B. , Floren , W. and Bakker , A. 2004 . Targeted delivery of RNA‐cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin‐modified, cyclodextrin‐based particles . Cancer Biol. & Ther. , 3 : 641 – 650 .
   PubMed Web of Science ®Google Scholar
• Bellocq , N. C. , Pun , S. H. , Jensen , G. S. and Davis , M. E. 2003 . Transferrin‐containing, cyclodextrin polymer‐based particles for tumor‐targeted gene delivery . Bioconjug. Chem. , 14 : 1122 – 1132 .
   PubMed Web of Science ®Google Scholar
• Pun , S. H. and Davis , M. E. 2002 . Development of a nonviral gene delivery vehicle for systemic application . Bioconjug. Chem. , 13 : 630 – 639 .
   PubMed Web of Science ®Google Scholar
• Hwang , S. J. , Bellocq , N. C. and Davis , M. E. 2001 . Effects of structure of beta‐cyclodextrin‐containing polymers on gene delivery . Bioconjug. Chem. , 12 : 280 – 290 .
   PubMed Web of Science ®Google Scholar
• Danhauserriedl , S. , Hausmann , E. , Schick , H. D. , Bender , R. , Dietzfelbinger , H. , Rastetter , J. and Hanauske , A. R. 1993 . Phase‐I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (Ad‐70, Dox‐Oxd) . Invest. New Drugs , 11 : 187 – 195 .
   PubMed Web of Science ®Google Scholar
• Inoue , K. , Kumazawa , E. , Kuga , H. , Susaki , H. , Masubuchi , N. and Kajimura , T. 2003 . CM‐dextran‐polyalcohol‐camptothecin conjugate: DE‐310 with a novel carrier system and its preclinical data . Adv. Exp. Med. Biol. , 519 : 145 – 153 .
   PubMed Web of Science ®Google Scholar
• Takimoto , C. H. , Lorusso , P. M. , Forero , L. , Schwartz , G. H. , Tolcher , A. W. , Patnaik , A. , Hammond , L. A. , Syed , S. , Simmons , C. , Ducharme , M. , De Jager , R. and Rowinsky , E. K. 2003 . A phase I and pharmacokinetic study of DE‐310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas . Clin. Cancer Res. , 9 : 6105s
   Google Scholar
• Kumazawa , E. and Ochi , Y. 2004 . DE‐310, a novel macromolecular carrier system for the camptothecin analog DX‐8951f: Potent antitumor activities in various murine tumor models . Cancer Science , 95 : 168 – 175 .
   Google Scholar
• Tomlinson , R. , Klee , M. , Garrett , S. , Heller , J. , Duncan , R. and Brocchini , S. 2002 . Pendent chain functionalized polyacetals that display pH‐dependent degradation: A platform for the development of novel polymer therapeutics . Macromolecules , 35 : 473 – 480 .
   Web of Science ®Google Scholar
• Vicent , M. J. , Tomlinson , R. , Brocchini , S. and Duncan , R. 2004 . Polyacetal‐diethylstilboestrol: A polymeric drug designed for pH‐triggered activation . J. Drug Target. , 12 : 491 – 501 .
   PubMed Web of Science ®Google Scholar
• Seymour , L. W. , Miyamoto , Y. , Maeda , H. , Brereton , M. , Strohalm , J. , Ulbrich , K. and Duncan , R. 1995 . Influence of molecular‐weight on passive tumor accumulation of a soluble macromolecular drug carrier . Eur. J. Cancer , 31A : 766 – 770 .
   PubMed Web of Science ®Google Scholar
• Noguchi , Y. , Wu , J. , Duncan , R. , Strohalm , J. , Ulbrich , K. , Akaike , T. and Maeda , H. 1998 . Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues . Jpn. J. Cancer Res. , 89 : 307 – 314 .
   PubMedGoogle Scholar
• Papisov , M. I. , Hiller , A. , Yurkovetskiy , A. , Yin , M. , Barzana , M. , Hillier , S. and Fischman , A. J. 2005 . Semisynthetic hydrophilic polyals . Biomacromolecules , 6 : 2659 – 2670 .
   Google Scholar
• Yurkovetskiy , A. , Choi , S. W. , Hiller , A. , Yin , M. , McCusker , C. , Syed , S. , Fischman , A. J. and Papisov , M. I. 2005 . Fully degradable hydrophilic polyals for protein modification . Biomacromolecules , 6 : 2648 – 2658 .
   PubMed Web of Science ®Google Scholar
• Burger , A. M. , Hartung , G. , Stehle , G. , Sinn , H. and Fiebig , H. H. 2001 . Pre‐clinical evaluation of a methotrexate‐albumin conjugate (MTX‐HSA) in human tumor xenografts in vivo . Int. J. Cancer , 92 : 718 – 724 .
   PubMed Web of Science ®Google Scholar
• Stehle , G. , Wunder , A. , Sinn , H. , Schrenk , H. H. , Schutt , S. , Frei , E. , Hartung , G. , Maier‐Borst , W. and Heene , D. L. 1997 . Pharmacokinetics of methotrexate‐albumin conjugates in tumor‐bearing rats . Anticancer. Drugs , 8 : 835 – 844 .
   PubMed Web of Science ®Google Scholar
• Hartung , G. , Stehle , G. , Sinn , H. , Wunder , A. , Schrenk , H. H. , Heeger , S. , Kranzle , M. , Edler , L. , Frei , E. , Fiebig , H. H. , Heene , D. L. , Maier‐Borst , W. and Queisser , W. 1999 . Phase I trial of methotrexate‐albumin in a weekly intravenous bolus regimen in cancer patients. Phase I study group of the association for medical oncology of the German Cancer Society . Clin. Cancer Res. , 5 : 753 – 759 .
   PubMed Web of Science ®Google Scholar
• Kratz , F. , Warnecke , A. , Scheuermann , K. , Stockmar , C. , Schwab , J. , Lazar , P. , Druckes , P. , Esser , N. , Drevs , J. , Rognan , D. , Bissantz , C. , Hinderling , C. , Folkers , G. , Fichtner , I. and Unger , C. 2002 . Probing the cysteine‐34 position of endogenous serum albumin with thiol‐binding doxorubicin derivatives. Improved efficacy of an acid‐sensitive doxorubicin derivative with specific albumin‐binding properties compared to that of the parent compound . J. Med. Chem. , 45 : 5523 – 5533 .
   PubMed Web of Science ®Google Scholar
• Drevs , J. , Mross , K. , Kratz , F. , Medinger , M. and Unger , C. 2004 . Phase I dose‐escalation and pharmacokinetic (PK) study of a(6‐maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO‐EMCH) in patients with advanced cancers . J. Clin. Oncol. , 22 : 158s – 158s .
   Google Scholar
• Fossella , F. V. , Tolcher , A. , Elliott , M. , Lambert , J. M. , Lu , R. , Zinner , R. , Lu , C. , Oh , Y. , Forouzesh , B. and McCreary , H. 2002 . Phase I trial of the monoclonal antibody conjugate, BB‐10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors . American Society of Clinical Oncology Annual Meeting ,
   Google Scholar
• Wu , A. M. and Senter , P. D. 2005 . Arming antibodies: prospects and challenges for immunoconjugates . Nat. Biotechnol. , 23 : 1137 – 1146 .
   PubMed Web of Science ®Google Scholar
• Vaishali Bagalkot , O. C. F. R. L. S. J. 2006 . An aptamer‐doxorubicin physical conjugate as a novel targeted drug‐delivery platform . Angew. Chem. Int. Ed. , 45 : 8149 – 8152 .
   Google Scholar
• Torchilin , V. P. 2005 . Block copolymer micelles as a solution for drug delivery problems . Expert Opin. Ther. Patents , 15 : 63 – 75 .
   Web of Science ®Google Scholar
• Huang , H. Y. , Remsen , E. E. , Kowalewski , T. and Wooley , K. L. 1999 . Nanocages derived from shell cross‐linked micelle templates . J. Am. Chem. Soc. , 121 : 3805 – 3806 .
   Web of Science ®Google Scholar
• Liu , H. B. , Jiang , A. , Guo , J. A. and Uhrich , K. E. 1999 . Unimolecular micelles: Synthesis and characterization of amphiphilic polymer systems . J. Polym. Sci. Part A: Polym. Chem. , 37 : 703 – 711 .
   Web of Science ®Google Scholar
• Hagan , S. A. , Coombes , A. G. A. , Garnett , M. C. , Dunn , S. E. , Davis , M. C. , Illum , L. , Davis , S. S. , Harding , S. E. , Purkiss , S. and Gellert , P. R. 1996 . Polylactide‐poly(ethylene glycol) copolymers as drug delivery systems. 1. Characterization of water dispersible micelle‐forming systems . Langmuir , 12 : 2153 – 2161 .
   Web of Science ®Google Scholar
• Kabanov , A. V. , Batrakova , E. V. and Alakhov , V. Y. 2002 . Pluronic (R) block copolymers as novel polymer therapeutics for drug and gene delivery . J. Controlled Release , 82 : 189 – 212 .
   PubMed Web of Science ®Google Scholar
• Avgoustakis , K. 2004 . Pegylated poly(lactide) and poly(lactide‐co‐glycolide) nanoparticles: preparation, properties and possible application in drug delivery . Current Drug Delivery , 1 : 321 – 333 .
   PubMedGoogle Scholar
• Kabanov , A. V. , Slepnev , V. I. , Kuznetsova , L. E. , Batrakova , E. V. , Alakhov , V. Y. , Melik‐Nubarov , N. S. and Sveshnikov , P. G. 1992 . Biochem. Int. , 26 : 1035
   Google Scholar
• Moghimi , S. M. and Davis , S. S. 1994 . Innovations in avoiding particle clearance from blood by kupffer cells — cause for reflection . Crit. Rev. Ther. Drug Carrier Syst. , 11 : 31 – 59 .
   PubMed Web of Science ®Google Scholar
• Cheng , J. , Teply , B. A. , Sherifi , I. , Sung , J. , Luther , G. , Gu , F. X. , Levy‐Nissenbaum , E. , Radovic‐Moreno , A. F. , Langer , R. and Farokhzad , O. C. 2007 . Formulation of functionalized PLGA‐PEG nanoparticles for in vivo targeted drug delivery . Biomaterials , 28 : 869 – 876 .
   PubMed Web of Science ®Google Scholar
• Kataoka , K. 1993 . Block copolymer micelles as vehicles for drug delivery . J. Control Release , 24 : 119 – 132 .
   Web of Science ®Google Scholar
• Yokoyama , M. , Sugiyama , T. , Okano , T. , Sakurai , Y. , Naito , M. and Kataoka , K. 1993 . Analysis of micelle formation of an adriamycin‐conjugated poly(ethylene glycol) poly(aspartic acid) block‐copolymer by gel‐permeation chromatography . Pharmaceut. Res. , 10 : 895 – 899 .
   PubMed Web of Science ®Google Scholar
• Matsumura , Y. , Hamaguchi , T. , Ura , T. , Muro , K. , Yamada , Y. , Shimada , Y. , Shirao , K. , Okusaka , T. , Ueno , H. , Ikeda , M. and Watanabe , N. 2004 . Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle‐encapsulated doxorubicin . Br. J. Cancer , 91 : 1775 – 1781 .
   PubMed Web of Science ®Google Scholar
• Yokoyama , M. , Satoh , A. , Sakurai , Y. , Okano , T. , Matsumura , Y. , Kakizoe , T. and Kataoka , K. 1998 . Incorporation of water‐insoluble anticancer drug into polymeric micelles and control of their particle size . J. Controlled Release , 55 : 219 – 229 .
   PubMed Web of Science ®Google Scholar
• Hamaguchi , T. , Matsumura , Y. , Suzuki , M. , Shimizu , K. , Goda , R. , Nakamura , I. , Nakatomi , I. , Yokoyama , M. , Kataoka , K. and Kakizoe , T. 2005 . NK105, a paclitaxel‐incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel . Br. J. Cancer , 92 : 1240 – 1246 .
   PubMed Web of Science ®Google Scholar
• Nishiyama , N. , Okazaki , S. , Cabral , H. , Miyamoto , M. , Kato , Y. , Sugiyama , Y. , Nishio , K. , Matsumura , Y. and Kataoka , K. 2003 . Novel cisplatin‐incorporated polymeric micelles can eradicate solid tumors in mice . Cancer Res. , 63 : 8977 – 8983 .
   PubMed Web of Science ®Google Scholar
• Sengupta , S. , Eavarone , D. , Capila , I. , Zhao , G. L. , Watson , N. , Kiziltepe , T. and Sasisekharan , R. 2005 . Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system . Nature , 436 : 568 – 572 .
   PubMed Web of Science ®Google Scholar
• Kim , S. C. , Kim , D. W. , Shim , Y. H. , Bang , J. S. , Oh , H. S. , Kim , S. W. and Seo , M. H. 2001 . In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy . J. Controlled Release , 72 : 191 – 202 .
   PubMed Web of Science ®Google Scholar
• Kim , T. Y. , Kim , D. W. , Chung , J. Y. , Shin , S. G. , Kim , S. C. , Heo , D. S. , Kim , N. K. and Bang , Y. J. 2004 . Phase I and pharmacokinetic study of Genexol‐PM, a cremophor‐free, polymeric micelle‐formulated paclitaxel, in patients with advanced malignancies . Clin. Cancer Res. , 10 : 3708 – 3716 .
   PubMed Web of Science ®Google Scholar
• Brannon‐Peppas , L. and Blanchette , J. O. 2004 . Nanoparticle and targeted systems for cancer therapy . Adv. Drug Deliv. Rev. , 56 : 1649 – 1659 .
   PubMed Web of Science ®Google Scholar
• Farokhzad , O. C. , Jon , S. Y. , Khadelmhosseini , A. , Tran , T. N. T. , LaVan , D. A. and Langer , R. 2004 . Nanopartide‐aptamer bioconjugates: A new approach for targeting prostate cancer cells . Cancer Res. , 64 : 7668 – 7672 .
   PubMed Web of Science ®Google Scholar
• Farokhzad , O. C. , Cheng , J. J. , Teply , B. A. , Sherifi , I. , Jon , S. , Kantoff , P. W. , Richie , J. P. and Langer , R. 2006 . Targeted nanoparticle‐aptamer bioconjugates for cancer chemotherapy in vivo . Proc. Natl. Acad. Sci. U.S.A. , 103 : 6315 – 6320 .
   PubMed Web of Science ®Google Scholar
• Gillies , E. R. and Frechet , J. M. J. 2003 . A new approach towards acid sensitive copolymer micelles for drug delivery . Chem. Comm. , : 1640 – 1641 .
   Google Scholar
• Bae , Y. , Fukushima , S. , Harada , A. and Kataoka , K. 2003 . Design of environment‐sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change . Angew. Chem. Int. Ed. , 42 : 4640 – 4643 .
   PubMed Web of Science ®Google Scholar
• Goodwin , A. P. , Mynar , J. L. , Ma , Y. Z. , Fleming , G. R. and Frechet , J. M. J. 2005 . Synthetic micelle sensitive to IR light via a two‐photon process . J. Am. Chem. Soc. , 127 : 9952 – 9953 .
   PubMed Web of Science ®Google Scholar
• Ahmed , F. and Discher , D. E. 2004 . Self‐porating polymersomes of PEG‐PLA and PEG‐PCL: hydrolysis‐triggered controlled release vesicles . J. Controlled Release , 96 : 37 – 53 .
   PubMed Web of Science ®Google Scholar
• Geng , Y. , Dalhaimer , P. , Cai , S. , Tsai , R. , Tewari , M. , Minko , T. and Discher , D. E. 2007 . Shape effects of filaments versus spherical particles in flow and drug delivery . Nat. Nanotechnol. , 2 : 249 – 255 .
   PubMed Web of Science ®Google Scholar
• Bilati , U. , Allemann , E. and Doelker , E. 2005 . Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles . Eur. J. Pharm. Sci. , 24 : 67 – 75 .
   PubMed Web of Science ®Google Scholar
• Peltonen , L. , Koistinen , P. and Hirvonen , J. 2003 . Preparation of nanoparticles by the nanoprecipitation of low molecular weight poly(l)lactide . S.T.P. Pharma. Sciences , 13 : 299 – 304 .
   Google Scholar
• Govender , T. , Stolnik , S. , Garnett , M. C. , Illum , L. and Davis , S. S. 1999 . PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug . J. Controlled Release , 57 : 171 – 185 .
   PubMed Web of Science ®Google Scholar
• Lemieux , P. , Vinogradov , S. V. , Gebhart , C. L. , Guerin , N. , Paradis , G. , Nguyen , H. K. , Ochietti , B. , Suzdaltseva , Y. G. , Bartakova , E. V. , Bronich , T. K. , St‐Pierre , Y. , Alakhov , V. Y. and Kabanov , A. V. 2000 . Block and graft copolymers and Nanogel (TM) copolymer networks for DNA delivery into cell . J. Drug Target. , 8 : 91 – 105 .
   PubMed Web of Science ®Google Scholar
• Yu , S. Y. , Hu , J. H. , Pan , X. Y. , Yao , P. and Jiang , M. 2006 . Stable and pH‐sensitive nanogels prepared by self‐assembly of chitosan and ovalbumin . Langmuir , 22 : 2754 – 2759 .
   PubMed Web of Science ®Google Scholar
• Vinogradov , S. V. , Batrakova , E. V. and Kabanov , A. V. 2004 . Nanogels for oligonucleotide delivery to the brain . Bioconjug. Chem. , 15 : 50 – 60 .
   PubMed Web of Science ®Google Scholar
• Vinogradov , S. V. , Bronich , T. K. and Kabanov , A. V. 2002 . Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells . Adv. Drug Deliv. Rev. , 54 : 135 – 147 .
   PubMed Web of Science ®Google Scholar
• Kabanov , A. V. and Batrakova , E. V. 2004 . New technologies for drug delivery across the blood brain barrier . Curr. Pharm. Des. , 10 : 1355 – 1363 .
   PubMed Web of Science ®Google Scholar
• Brigger , I. , Dubernet , C. and Couvreur , P. 2002 . Nanoparticles in cancer therapy and diagnosis . Adv. Drug Deliv. Rev. , 54 : 631 – 651 .
   PubMed Web of Science ®Google Scholar
• Otsuka , H. , Nagasaki , Y. and Kataoka , K. 2003 . PEGylated nanoparticles for biological and pharmaceutical applications . Adv. Drug Deliv. Rev. , 55 : 403 – 419 .
   PubMed Web of Science ®Google Scholar
• Panyam , J. and Labhasetwar , V. 2003 . Biodegradable nanoparticles for drug and gene delivery to cells and tissue . Adv. Drug Deliv. Rev. , 55 : 329 – 347 .
   PubMed Web of Science ®Google Scholar
• Liang , X. M. , Mao , G. Z. and Ng , K. Y. S. 2005 . Effect of chain lengths of PEO‐PPO‐PEO on small unilamellar liposome morphology and stability: an AFM investigation . J. Colloid Interface Sci. , 285 : 360 – 372 .
   PubMed Web of Science ®Google Scholar
• Yang , Z. G. , Yuan , J. J. and Cheng , S. Y. 2005 . Self‐assembling of biocompatible BAB amphiphilic triblock copolymers PLL(Z)‐PEG‐PLL(Z) in aqueous medium . Eur. Polym. J. , 41 : 267 – 274 .
   Google Scholar
• Yuan , J. J. , Li , Y. S. , Li , X. Q. , Cheng , S. Y. , Jiang , L. , Feng , L. X. and Fan , Z. Q. 2003 . The “crew-cut” aggregates of polystyrene-b-poly(ethylene oxide)-b-polystyrene triblock copolymers in aqueous media . Eur. Polym. J. , 39 : 767 – 776 .
   Google Scholar
• Liu , F. T. and Eisenberg , A. 2003 . Preparation and pH triggered inversion of vesicles from poly(acrylic acid)‐block‐polystyrene‐block‐poly(4‐vinyl pyridine) . J. Am. Chem. Soc. , 125 : 15059 – 15064 .
   PubMed Web of Science ®Google Scholar
• Brannan , A. K. and Bates , F. S. 2004 . ABCA tetrablock copolymer vesicles . Macromolecules , 37 : 8816 – 8819 .
   Web of Science ®Google Scholar
• Discher , B. M. , Hammer , D. A. , Bates , F. S. and Discher , D. E. 2000 . Polymer vesicles in various media . Curr. Opin. Colloid Interface Sci. , 5 : 125 – 131 .
   Web of Science ®Google Scholar
• Fasman , G. 1989 . Prediction of Protein Structure and the Principles of Protein Conformation New York : Plenum .
   Google Scholar
• Yu , M. , Nowak , A. P. , Deming , T. J. and Pochan , D. J. 1999 . Methylated mono‐ and diethyleneglycol functionalized polylysines: Nonionic, alpha‐helical, water‐soluble polypeptides . J. Am. Chem. Soc. , 121 : 12210 – 12211 .
   Web of Science ®Google Scholar
• Musumeci , T. , Ventura , C. A. , Giannone , I. , Ruozi , B. , Montenegro , L. , Pignatello , R. and Puglisi , G. 2006 . PLA/PLGA nanoparticles for sustained release of docetaxel . Int. J. Pharm. , 325 : 172 – 179 .
   PubMed Web of Science ®Google Scholar
• Frankel , A. D. and Pabo , C. O. 1988 . Cellular uptake of the tat protein from human immunodeficiency virus . Cell , 55 : 1189 – 1193 .
   PubMed Web of Science ®Google Scholar
• Buhleier , E. , Wehner , W. and Vogtle , F. 1978 . Cascade‐chain‐like and nonskid‐chain‐like syntheses of molecular cavity topologies . Synthesis‐Stuttgart , : 155 – 158 .
   Google Scholar
• Tomalia , D. A. , Baker , H. , Dewald , J. , Hall , M. , Kallos , G. , Martin , S. , Roeck , J. , Ryder , J. and Smith , P. 1985 . A new class of polymers—starburst‐dendritic macromolecules . Polym. J. , 17 : 117 – 132 .
   Web of Science ®Google Scholar
• Newkome , G. R. , Yao , Z. Q. , Baker , G. R. and Gupta , V. K. 1985 . Micelles. 1. cascade molecules — a new approach to micelles — a [27]‐arborol . J. Org. Chem. , 50 : 2003 – 2004 .
   Web of Science ®Google Scholar
• Aulenta , F. , Hayes , W. and Rannard , S. 2003 . Dendrimers: a new class of nanoscopic containers and delivery devices . Eur. Polym. J. , 39 : 1741 – 1771 .
   Web of Science ®Google Scholar
• Esfand , R. and Tomalia , D. A. 2001 . Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications . Drug Discovery Today , 6 : 427 – 436 .
   PubMed Web of Science ®Google Scholar
• Hawker , C. J. and Frechet , J. M. J. 1990 . Preparation of polymers with controlled molecular architecture — a new convergent approach to dendritic macromolecules . J. Am. Chem. Soc. , 112 : 7638 – 7647 .
   Web of Science ®Google Scholar
• Hawker , C. and Frechet , J. M. J. 1990 . A new convergent approach to monodisperse dendritic macromolecules . J. Chem. Soc. Chem. Commun. , : 1010 – 1013 .
   Google Scholar
• Zeng , F. W. and Zimmerman , S. C. 1997 . Dendrimers in supramolecular chemistry: From molecular recognition to self‐assembly . Chem. Rev. , 97 : 1681 – 1712 .
   PubMed Web of Science ®Google Scholar
• Zimmerman , S. C. 1997 . Dendrimers in molecular recognition and self‐assembly . Curr. Opin. Colloid Interface Sci. , 2 : 89 – 99 .
   Google Scholar
• Matthews , O. A. , Shipway , A. N. and Stoddart , J. F. 1998 . Dendrimers‐Branching out from curiosities into new technologies . Prog. Polym. Sci. , 23 : 1 – 56 .
   Web of Science ®Google Scholar
• Bosman , A. W. , Janssen , H. M. and Meijer , E. W. 1999 . About dendrimers: Structure, physical properties, and applications . Chem. Rev. , 99 : 1665 – 1688 .
   PubMed Web of Science ®Google Scholar
• Fischer , M. and Vogtle , F. 1999 . Dendrimers: From design to application—A progress report . Angew. Chem. Int. Ed. , 38 : 885 – 905 .
   Web of Science ®Google Scholar
• Liang , C. O. and Frechet , J. M. J. 2005 . Incorporation of functional guest molecules into an internally functionalizable dendrimer through olefin metathesis . Macromolecules , 38 : 6276 – 6284 .
   Web of Science ®Google Scholar
• Tomalia , D. A. 2005 . Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry . Prog. Polym. Sci. , 30 : 294 – 324 .
   Web of Science ®Google Scholar
• Yang , H. and Kao , W. Y. J. 2006 . Dendrimers for pharmaceutical and biomedical applications . J. Biomater. Sci.‐Polym. Ed. , 17 : 3 – 19 .
   PubMed Web of Science ®Google Scholar
• Liu , M. J. and Frechet , J. M. J. 1999 . Designing dendrimers for drug delivery . Pharma. Sci. Tech. Tod. , 2 : 393 – 401 .
   PubMedGoogle Scholar
• Gillies , E. R. and Frechet , J. M. J. 2005 . Dendrimers and dendritic polymers in drug delivery . Drug Discov. Today , 10 : 35 – 43 .
   PubMed Web of Science ®Google Scholar
• Florence , A. T. and Hussain , N. 2001 . Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas . Adv. Drug Deliv. Rev. , 50 : S69 – S89 .
   PubMed Web of Science ®Google Scholar
• Patri , A. K. , Majoros , I. J. and Baker , J. R. 2002 . Dendritic polymer macromolecular carriers for drug delivery . Curr. Opin. Chem. Biol. , 6 : 466 – 471 .
   PubMed Web of Science ®Google Scholar
• Patri , A. K. , Kukowska‐Latallo , J. F. and Baker , J. R. 2005 . Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non‐covalent drug inclusion complex . Adv. Drug Deliv. Rev. , 57 : 2203 – 2214 .
   PubMed Web of Science ®Google Scholar
• Dufes , C. , Uchegbu , I. F. and Schatzlein , A. G. 2005 . Dendrimers in gene delivery . Adv. Drug Deliv. Rev. , 57 : 2177 – 2202 .
   PubMed Web of Science ®Google Scholar
• D'Emanuele , A. and Attwood , D. 2005 . Dendrimer‐drug interactions . Adv. Drug Deliv. Rev. , 57 : 2147 – 2162 .
   PubMed Web of Science ®Google Scholar
• Kitchens , K. M. , El‐Sayed , M. E. H. and Ghandehari , H. 2005 . Transepithelial and endothelial transport of poly(amidoamine) dendrimers . Adv. Drug Deliv. Rev. , 57 : 2163 – 2176 .
   PubMed Web of Science ®Google Scholar
• Jang , W. D. and Kataoka , K. 2005 . Bioinspired applications of functional dendrimers . J. Drug Deliv. Sci. Technol. , 15 : 19 – 30 .
   Google Scholar
• Kukowska‐Latallo , J. F. , Candido , K. A. , Cao , Z. Y. , Nigavekar , S. S. , Majoros , I. J. , Thomas , T. P. , Balogh , L. P. , Khan , M. K. and Baker , J. R. 2005 . Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer . Cancer Res. , 65 : 5317 – 5324 .
   PubMed Web of Science ®Google Scholar
• Kramer , M. , Stumbe , J. F. , Turk , H. , Krause , S. , Komp , A. , Delineau , L. , Prokhorova , S. , Kautz , H. and Haag , R. 2002 . pH‐responsive molecular nanocarriers based on dendritic core‐shell architectures . Angew. Chem. Int. Ed. , 41 : 4252 – 4256 .
   PubMed Web of Science ®Google Scholar
• Greenwald , R. B. , Pendri , A. , Conover , C. D. , Lee , C. , Choe , Y. H. , Gilbert , C. , Martinez , A. , Xia , J. , Wu , D. C. and Hsue , M. 1998 . Camptothecin‐20‐PEG ester transport forms: the effect of spacer groups on antitumor activity . Bioorg. Med. Chem. , 6 : 551 – 562 .
   PubMed Web of Science ®Google Scholar
• Tibben , M. M. , Rademaker‐Lakhai , J. M. , Rice , J. R. , Stewart , D. R. , Schellens , J. H. M. and Beijnen , J. H. 2002 . Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum‐containing N‐(2‐hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite‐furnace Zeeman atomic‐absorption spectrometry . Anal. & Bioanal. Chem. , 373 : 233 – 236 .
   PubMed Web of Science ®Google Scholar
• Rademaker‐Lakhai , J. M. , Terret , C. , Howell , S. B. , Baud , C. M. , De Boer , R. , Beijnen , J. H. , Schellens , J. H. M. and Droz , J. P. 2003 . A Phase I study of the platinum (Pt) polymer AP5280 as an intravenous infusion once every three weeks in patients with a solid tumor . Br. J. Clin. Pharmacol. , 56 : 469 – 469 .
   Google Scholar
• Lin , X. , Zhang , Q. , Rice , J. R. , Stewart , D. R. , Nowotnik , D. P. and Howell , S. B. 2004 . Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models . Eur. J. Cancer , 40 : 291 – 297 .
   PubMed Web of Science ®Google Scholar
• Rademaker‐Lakhai , J. M. , Terret , C. , Howell , S. B. , Baud , C. M. , de Boer , R. F. , Pluim , D. , Beijnen , J. H. , Schellens , J. H. M. and Droz , J. P. 2004 . A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors . Clin. Cancer Res. , 10 : 3386 – 3395 .
   PubMed Web of Science ®Google Scholar
• Rice , J. R. , Gerberich , J. L. , Nowotnik , D. P. and Howell , S. B. 2006 . Preclinical efficacy and pharmacokinetics of ap5346, a novel diaminocyclohexane‐platinum tumor‐targeting drug delivery system . Clin. Cancer Res. , 12 : 2248 – 2254 .
   PubMed Web of Science ®Google Scholar
• Nemunaitis , J. , Cunningham , C. , Senzer , N. , Gray , M. , Oldham , F. , Pippen , J. , Mennel , R. and Eisenfeld , A. 2005 . Phase I study of CT‐2103, a polymer‐conjugated paclitaxel, and carboplatin in patients with advanced solid tumors . Cancer Invest. , 23 : 671 – 676 .
   PubMed Web of Science ®Google Scholar
• Langer , C. J. 2004 . CT‐2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes . Clin. Lung Cancer , 6 ( Suppl 2 ) : S85 – 88 .
   PubMedGoogle Scholar
• Langer , C. J. 2004 . CT‐2103: emerging utility and therapy for solid tumours . Expert Opin. Investig. Drugs , 13 : 1501 – 1508 .
   PubMed Web of Science ®Google Scholar
• Graefe , T. , Bolling , C. , Lubbing , C. , Latz , J. , Blatter , J. and Hanauske , A. 2006 . Pemetrexed in combination with paclitaxel: A phase I clinical and pharmacokinetic trial in patients with solid tumors . J. Clin. Oncol. , 24 : 91s – 91s .
   Google Scholar
• Graefe , T. , Lubbing , C. , Bolling , C. , Muller‐Hagen , S. , Leisner , B. , Fleet , J. , Ludtke , F. E. , Blatter , J. , Suri , A. and Hanauske , A. R. 2004 . Phase I study of pemetrexed plus paclitaxel in patients with solid tumor . J. Clin. Oncol. , 22 : 152s – 152s .
   Google Scholar
• Bolling , C. , Lubbing , C. , Graefe , T. , Mack , S. , Von Scheel , J. , Muller‐Hagen , S. , Blatter , J. , Depenbrock , H. , Ohnmacht , U. and Hanauske , A. R. 2004 . Pemetrexed/gemcitabine/cisplatin: Phase I trial in patients with solid tumors . J. Clin. Oncol. , 22 : 218s – 218s .
   Google Scholar
• Holen , K. D. , Bolling , C. , Saltz , L. B. , Graefe , T. , Ty , V. , Sogo , N. , Starkmann , H. , Burk , K. H. , Hollywood , E. and Hanauske , A. R. 2003 . Phase I and pharimacokinetic trial of a novel inhibitor of NAD biosynthesis in patients with solid tumors . Clin. Cancer Res. , 9 : 6158s – 6158s .
   Google Scholar
• Kwon , G. , Suwa , S. , Yokoyama , M. , Okano , T. , Sakurai , Y. and Kataoka , K. 1994 . Enhanced tumor accumulation and prolonged circulation times of micelle‐forming poly(ethylene oxide‐aspartate) block copolymer‐adriamycin conjugates . J. Controlled Release , 29 : 17 – 23 .
   Web of Science ®Google Scholar
• Kataoka , K. , Matsumoto , T. , Yokoyama , M. , Okano , T. , Sakurai , Y. , Fukushima , S. , Okamoto , K. and Kwon , G. S. 2000 . Doxorubicin‐loaded poly(ethylene glycol)‐poly(beta‐benzyl‐l‐aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance . J. Controlled Release , 64 : 143 – 153 .
   PubMed Web of Science ®Google Scholar
• Yokoyama , M. , Kwon , G. S. , Okano , T. , Sakurai , Y. , Naito , M. and Kataoka , K. 1994 . Influencing factors on in‐vitro micelle stability of adriamycin‐block copolymer conjugates . J. Controlled Release , 28 : 59 – 65 .
   Web of Science ®Google Scholar
• Kwon , G. S. , Yokoyama , M. , Okano , T. , Sakurai , Y. and Kataoka , K. 1994 . Enhanced tumor accumulation and prolonged circulation times of micelle‐forming poly(ethylene oxide‐aspartate) block copolymer‐adriamycin conjugates . J. Controlled Release , 28 : 334 – 335 .
   Web of Science ®Google Scholar
• Yokoyama , M. , Fukushima , S. , Uehara , R. , Okamoto , K. , Kataoka , K. , Sakurai , Y. and Okano , T. 1998 . Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor . J. Controlled Release , 50 : 79 – 92 .
   PubMed Web of Science ®Google Scholar
• Li , Y. and Kwon , G. S. 2000 . Methotrexate esters of poly(ethylene oxide)‐block‐poly(2‐hydroxyethyl‐L‐aspartamide). Part I: Effects of the level of methotrexate conjugation on the stability of micelles and on drug release . Pharm. Res. , 17 : 607 – 611 .
   PubMed Web of Science ®Google Scholar
• La , S. B. , Okano , T. and Kataoka , K. 1996 . Preparation and characterization of the micelle‐forming polymeric drug indomethacin‐incorporated poly(ethylene oxide)‐poly(beta‐benzyl‐L‐aspartate) block copolymer micelles . J. Pharm. Sci. , 85 : 85 – 90 .
   PubMed Web of Science ®Google Scholar
• Yu , B. G. , Okano , T. , Kataoka , K. , Sardari , S. and Kwon , G. S. 1998 . In vitro dissociation of antifungal efficacy and toxicity for amphotericin B‐loaded poly(ethylene oxide)‐block‐poly(beta‐benzyl‐L‐aspartate) micelles . J. Controlled Release , 56 : 285 – 291 .
   PubMed Web of Science ®Google Scholar
• Adams , M. L. and Kwon , G. S. 2003 . Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)‐block‐poly(N‐hexyl‐L‐aspartamide)‐acyl conjugate micelles: effects of acyl chain length . J. Controlled Release , 87 : 23 – 32 .
   PubMed Web of Science ®Google Scholar
• Lavasanifar , A. , Samuel , J. and Kwon , G. S. 2002 . The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly(ethylene oxide)‐block‐poly(N‐hexyl stearate‐L‐aspartamide) . J. Controlled Release , 79 : 165 – 172 .
   PubMed Web of Science ®Google Scholar
• Lavasanifar , A. , Samuel , J. and Kwon , G. S. 2001 . Micelles self‐assembled from poly(ethylene oxide)‐block‐poly(N‐hexyl stearate L‐aspartamide) by a solvent evaporation method: effect on the solubilization and haemolytic activity of amphotericin B . J. Controlled Release , 77 : 155 – 160 .
   PubMed Web of Science ®Google Scholar
• Nishiyama , N. and Kataoka , K. 2001 . Preparation and characterization of size‐controlled polymeric micelle containing cis‐dichlorodiammineplatinum(II) in the core . J. Controlled Release , 74 : 83 – 94 .
   PubMed Web of Science ®Google Scholar
• Mizumura , Y. , Matsumura , Y. , Hamaguchi , T. , Nishiyama , N. , Kataoka , K. , Kawaguchi , T. , Hrushesky , W. J. M. , Moriyasu , F. and Kakizoe , T. 2001 . Cisplatin‐incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity . Jpn. J. Cancer Res. , 92 : 328 – 336 .
   PubMedGoogle Scholar
• Jeong , Y. I. , Cheon , J. B. , Kim , S. H. , Nah , J. W. , Lee , Y. M. , Sung , Y. K. , Akaike , T. and Cho , C. S. 1998 . Clonazepam release from core‐shell type nanoparticles in vitro . J. Controlled Release , 51 : 169 – 178 .
   PubMed Web of Science ®Google Scholar
• Lee , E. S. , Na , K. and Bae , Y. H. 2005 . Doxorubicin loaded pH‐sensitive polymeric micelles for reversal of resistant MCF‐7 tumor . J. Controlled Release , 103 : 405 – 418 .
   PubMed Web of Science ®Google Scholar
• Lee , E. S. , Na , K. and Bae , Y. H. 2005 . Super pH‐sensitive multifunctional polymeric micelle . Nano Lett. , 5 : 325 – 329 .
   PubMed Web of Science ®Google Scholar
• Bogdanov , A. A. , Martin , C. , Bogdanova , A. V. , Brady , T. J. and Weissleder , R. 1996 . An adduct of cis‐diamminedichloroplatinum (II) and poly(ethylene glycol)poly(L‐lysine)‐succinate: Synthesis and cytotoxic properties . Bioconjug. Chem. , 7 : 144 – 149 .
   PubMed Web of Science ®Google Scholar
• Shin , I. L. G. , Kim , S. Y. , Lee , Y. M. , Cho , C. S. and Sung , Y. K. 1998 . Methoxy poly(ethylene glycol) epsilon‐caprolactone amphiphilic block copolymeric micelle containing indomethacin. I. Preparation and characterization . J. Controlled Release , 51 : 1 – 11 .
   PubMed Web of Science ®Google Scholar
• Kim , S. Y. , Shin , I. L. G. , Lee , Y. M. , Cho , C. S. and Sung , Y. K. 1998 . Methoxy poly(ethylene glycol) and epsilon‐caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviours . J. Controlled Release , 51 : 13 – 22 .
   PubMed Web of Science ®Google Scholar
• Allen , C. , Han , J. N. , Yu , Y. S. , Maysinger , D. and Eisenberg , A. 2000 . Polycaprolactone‐b‐poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone . J. Controlled Release , 63 : 275 – 286 .
   PubMed Web of Science ®Google Scholar
• Allen , C. , Yu , Y. S. , Maysinger , D. and Eisenberg , A. 1998 . Polycaprolactone‐b‐poly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L‐685,818 . Bioconjug. Chem. , 9 : 564 – 572 .
   PubMed Web of Science ®Google Scholar
• Ge , H. X. , Hu , Y. , Jiang , X. Q. , Cheng , D. M. , Yuan , Y. Y. , Bi , H. and Yang , C. Z. 2002 . Preparation, characterization, and drug release behaviors of drug nimodipine‐loaded poly(epsilon‐caprolactone)‐poly(ethylene oxide)‐poly(epsilon‐caprolactone) amphiphilic triblock copolymer micelles . J. Pharm. Sci. , 91 : 1463 – 1473 .
   PubMed Web of Science ®Google Scholar
• Burt , H. M. , Zhang , X. C. , Toleikis , P. , Embree , L. and Hunter , W. L. 1999 . Development of copolymers of poly(D,L‐lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel . Colloid Surf. B , 16 : 161 – 171 .
   Web of Science ®Google Scholar
• Zhang , X. C. , Jackson , J. K. and Burt , H. M. 1996 . Development of amphiphilic diblock copolymers as micellar carriers of taxol . Int. J. Pharm. , 132 : 195 – 206 .
   Web of Science ®Google Scholar
• Dong , Y. C. and Feng , S. S. 2004 . Methoxy poly(ethylene glycol)‐poly(lactide) (MPEG‐PLA) nanoparticles for controlled delivery of anticancer drugs . Biomaterials , 25 : 2843 – 2849 .
   PubMed Web of Science ®Google Scholar
• Liu , L. , Li , C. X. , Li , X. C. , Yuan , Z. , An , Y. L. and He , B. L. 2001 . Biodegradable polylactide/poly(ethylene glycol)/polylactide triblock copolymer micelles as anticancer drug carriers . J. Appl. Polym. Sci , 80 : 1976 – 1982 .
   Web of Science ®Google Scholar
• Yoo , H. S. and Park , T. G. 2001 . Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA‐PEG block copolymer . J. Controlled Release , 70 : 63 – 70 .
   PubMed Web of Science ®Google Scholar
• Mu , L. and Feng , S. S. 2003 . A novel controlled release formulation for the anticancer drug paclitaxel (Taxol(R)): PLGA nanoparticles containing vitamin E TPGS . J. Controlled Release , 86 : 33 – 48 .
   PubMed Web of Science ®Google Scholar
• Alakhov , V. Y. , Moskaleva , E. Y. , Batrakova , E. V. and Kabanov , A. V. 1996 . Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer . Bioconjug. Chem. , 7 : 209 – 216 .
   PubMed Web of Science ®Google Scholar
• Venne , A. , Li , S. M. , Mandeville , R. , Kabanov , A. and Alakhov , V. 1996 . Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug‐resistant cells . Cancer Res. , 56 : 3626 – 3629 .
   PubMed Web of Science ®Google Scholar
• Batrakova , E. V. , Li , S. , Miller , D. W. and Kabanov , A. V. 1999 . Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco‐2 cell monolayers . Pharm. Res. , 16 : 1366 – 1372 .
   PubMed Web of Science ®Google Scholar
• Batrakova , E. V. , Miller , D. W. , Li , S. , Alakhov , V. Y. , Kabanov , A. V. and Elmquist , W. F. 2001 . Pluronic P85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies . J. Pharmacol. Exp. Ther. , 296 : 551 – 557 .
   PubMed Web of Science ®Google Scholar
• Aramwit , P. , Yu , B. G. , Lavasanifar , A. , Samuel , J. and Kwon , G. S. 2000 . The effect of serum albumin on the aggregation state and toxicity of amphotericin B . J. Pharm. Sci. , 89 : 1589 – 1593 .
   PubMed Web of Science ®Google Scholar
• Jiang , J. Q. , Tong , X. and Zhao , Y. 2005 . A new design for light‐breakable polymer micelles . J. Am. Chem. Soc. , 127 : 8290 – 8291 .
   PubMed Web of Science ®Google Scholar
• Li , Y. Y. , Zhang , X. Z. , Cheng , H. , Kim , G. C. , Cheng , S. X. and Zhuo , R. X. 2006 . Novel stimuli‐responsive micelle self‐assembled from Y‐shaped P(UA‐Y‐NIPAAm) copolymer for drug delivery . Biomacromolecules , 7 : 2956 – 2960 .
   PubMed Web of Science ®Google Scholar
• Nakayama , M. , Okano , T. , Miyazaki , T. , Kohori , F. , Sakai , K. and Yokoyama , M. 2006 . Molecular design of biodegradable polymeric micelles for temperature‐responsive drug release . J. Controlled Release , 115 : 46 – 56 .
   PubMed Web of Science ®Google Scholar
• Wang , C. H. , Wang , C. H. and Hsiue , G. H. 2005 . Polymeric micelles with a pH‐responsive structure as intracellular drug carriers . J. Controlled Release , 108 : 140 – 149 .
   PubMed Web of Science ®Google Scholar
• Wang , C. , Ge , Q. , Ting , D. , Nguyen , D. , Shen , H. R. , Chen , J. Z. , Eisen , H. N. , Heller , J. , Langer , R. and Putnam , D. 2004 . Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines . Nat. Mater. , 3 : 190 – 196 .
   PubMed Web of Science ®Google Scholar
• Lynn , D. M. , Amiji , M. M. and Langer , R. 2001 . pH‐responsive polymer microspheres: Rapid release of encapsulated material within the range of intracellular pH . Angew. Chem. Int. Ed. , 40 : 1707 – 1710 .
   PubMed Web of Science ®Google Scholar
• Kim , M. S. , Hwang , S. J. , Han , J. K. , Choi , E. K. , Park , H. J. , Kim , J. S. and Lee , D. S. 2006 . pH‐responsive PEG‐poly(beta‐amino ester) block copolymer micelles with a sharp transition . Macromol. Rapid. Commun. , 27 : 447 – 451 .
   Web of Science ®Google Scholar
• Heffernan , M. J. and Murthy , N. 2005 . Polyketal nanoparticles: A new pH‐sensitive biodegradable drug delivery vehicle . Bioconjug. Chem. , 16 : 1340 – 1342 .
   PubMed Web of Science ®Google Scholar